Clinical TrialsSearch results
Number of results: 2568
Recruiting
- A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors
- Gastric cancer Gastro-esophageal junction cancer Pancreatic ductal adenocarcinoma Esophageal aden
- Hibi Kazushige
- 2023-07-01
Recruiting
- A phase I/II study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting
- Heart failure with ischemic heart disease
- Kaneko Takehiko
- 2021-06-23
Recruiting
- A Phase I/II Study of necitumumab + carboplatin + nab-paclitaxel + pembrolizumab for previously untreated advanced squamous non-small cell lung cancer study
- squamous non-small cell lung cancer(SqCLC)
- Seike Masahiro
- 2021-10-22
Recruiting
- A Phase I/II.a Investigator-initiated Study of ADR-001 in Combination With Nivolumab in Cancer Patients With Acquired Resistance to Immune Checkpoint Inhibitors
- Solid cancers such as lung cancer, esophageal cancer, stomach cancer, etc.
- Wada Satoshi
- 2024-04-10
Recruiting
- A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
- Hibi Kazushige
- 2022-01-28
Recruiting
- A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.
- Advanced or Metastatic Solid Tumors
- Hibi Kazushige
- 2023-03-02
Recruiting
- A PHASE Ib STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7496353 IN COMBINATION WITH A CHECKPOINT INHIBITOR WITH OR WITHOUT STANDARD-OF-CARE CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METAS
- solid tumor
- Eunpi Cho
- 2023-07-13
Recruiting
- A phase II study by using CICS-1 and SPM-011 commissioned by CICS and STELLA PHARMA
- Unresectable angiosarcoma
- Hayashi Toshimitsu
- 2022-10-26
Recruiting
- A phase II study to assess the efficacy, safety and pharmacokinetics of M529101 for pain in oral mucositis derived from head and neck cancer treatment.
- Pain in oral mucositis derived from head and neck cancer treatment
- Tomoyuki Nishiura
- 2022-10-28
Recruiting
- A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Partisipants with Advanced Solid Tumours Expressing Claudin18.2. NOTE: Official Title should have no more than 240 characters.
- Gastric cancer, Gastroesophageal junction cancer, Pancreatic Adenocarcinoma
- Hibi Kazushige
- 2024-01-16